KRAS and colorectal cancer: The old RASCAL II study, for example (13), suggested that in resected colorectal cancer patients stratified by KRAS mutational status, those harboring G12V mutations (8.6% of the analyzed population) were those with the higher risk of disease relapse, while other KRAS mutations did not have a prognostic impact.